Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Petrie

Showing results (491-500 of 557) with videos related to

Pageof 56
Sort By:
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
Circulation. Heart Failure|September 29, 2024
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HFMisato Chimura, Mark C Petrie, Morten Schou, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 31, 2024
Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESCPetr Peichl, Antoni Bayes-Genis, Thomas Deneke, et al.
European Journal of Heart Failure|December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HFPooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.
European Journal of Heart Failure|July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexCarly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
Journal of the American College of Cardiology|November 20, 2024
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart FailureMikhail N Kosiborod, David Z I Cherney, Akshay S Desai, et al.
European Journal of Heart Failure|May 24, 2024
Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESCGiuseppe M C Rosano, Davide Stolfo, Lisa Anderson, et al.
European Journal of Heart Failure|December 26, 2024
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trialMark C Petrie, Jacob A Udell, Stefan D Anker, et al.
International Journal of Cardiology|April 2, 2019
Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trialJose C Nicolau, Susanna R Stevens, Hussein R Al-Khalidi, et al.
Pageof 56

Showing results (491-500 of 557) with videos related to

Sort By:
Pageof 56
European Journal of Heart Failure|November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HFJawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JAMA Cardiology|March 5, 2025
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HFKirsty McDowell, Kieran F Docherty, Ross T Campbell, et al.
Circulation. Heart Failure|September 29, 2024
Finerenone Improves Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HFMisato Chimura, Mark C Petrie, Morten Schou, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 31, 2024
Drug therapy and catheter ablation for management of arrhythmias in continuous flow left ventricular assist device's patients: a Clinical Consensus Statement of the European Heart Rhythm Association and the Heart Failure Association of the ESCPetr Peichl, Antoni Bayes-Genis, Thomas Deneke, et al.
European Journal of Heart Failure|December 28, 2020
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HFPooja Dewan, Kieran F Docherty, Olof Bengtsson, et al.
European Journal of Heart Failure|July 17, 2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass indexCarly Adamson, Pardeep S Jhund, Kieran F Docherty, et al.
Journal of the American College of Cardiology|November 20, 2024
Sodium Zirconium Cyclosilicate for Management of Hyperkalemia During Spironolactone Optimization in Patients With Heart FailureMikhail N Kosiborod, David Z I Cherney, Akshay S Desai, et al.
European Journal of Heart Failure|May 24, 2024
Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the Heart Failure Association of the ESCGiuseppe M C Rosano, Davide Stolfo, Lisa Anderson, et al.
European Journal of Heart Failure|December 26, 2024
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trialMark C Petrie, Jacob A Udell, Stefan D Anker, et al.
International Journal of Cardiology|April 2, 2019
Does prior coronary angioplasty affect outcomes of surgical coronary revascularization? Insights from the STICH trialJose C Nicolau, Susanna R Stevens, Hussein R Al-Khalidi, et al.
Pageof 56